iBio, Inc. 

iBio, Inc. (NYSE: IBIO) is a biopharmaceutical developer and the inventor of the sustainable FastPharming Manufacturing System. Using licensed and owned technologies, the company develops novel treatments to prevent fibrotic disorders, malignancies, and infectious diseases. 

Key Highlights: 

• The company reported a significant decline in revenues to USD 211 thousand in Q1FY22 (ended September 30, 2021) compared to USD 410 thousand in Q1FY21. 
• IBIO generated 100% of its revenue from three clients in Q1FY22, with two customers accounting for 81% of revenue; losing any customer could negatively influence the company's top line in the future. 
• IBIO reported an increase in net losses to USD 8.94 million in Q1FY22 from USD 7.53 million in Q1FY21. 
• In Q1FY22, the company's average receivable days were 2,336 days, compared to the industry median of 60.5 days. 
• The stock is now trading below its key short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 36.66, indicating a bearish trend. 

• Stock is leaning towards the lower band of the 52-week range of USD 0.39 to USD 2.83. 
• IBIO stock price has fallen 66.38 and 72.24% in the past six and nine months, respectively. 

Three-Year Technical Price Chart (as of February 10, 2022; 12:33 PM ET). Analysis by Kalkine Group 

Conclusion: Considering the bottom-line stress, uncertain outlook, insignificant topline, reliance on specific customers, and other technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 0.4136, down 1.52% as of February 10, 2022, at 12:33 PM ET. 

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.